PODD: Inverse Head And Shoulders detected on 22 Sep 2026

PODD is forming an inverse head and shoulders pattern after significant declines following Q2 earnings on August 5, 2026, which showed $801.7 million revenue up 23.5%. Current price sits at $140.53, testing key support at $138.28 with resistance at $97.65. The pattern quality scores show structure at 11.0, volume at 12.0, and breakout at 12.0, indicating a moderately formed setup. RSI at 45.1 suggests neutral momentum, while volume ratio of 0.73 reflects below-average participation. Conservative breakout target is $147.61, approximately 5% above current levels.

Q2 2026 revenue of $801.7 million exceeded guidance at 23.5% growth, with U.S. Omnipod revenue up 20.1% and international up 35.5%. However, despite strong Q2 results, Insulet trimmed its 2026 revenue growth guidance, leading to investor caution. On May 26, 2026, BTIG cut its valuation multiple from 4.5x to 4x citing 'continued negative investor sentiment' and regulatory scrutiny from a second voluntary medical device correction. PODD shares declined from $236.07 to $146.01 after two corrective disclosures, with the second affecting approximately 7 million Pods representing 8.5% of 2025 global production. The pattern appears to be forming as oversold recovery after severe punishment.

A successful breakout above $147.61 would confirm the inverse head and shoulders completion, targeting approximately $147-148 near-term with potential extension toward pre-correction highs. The pattern has a win probability of 63.44%, suggesting better-than-coin-flip odds for upside. Volume confirmation would require a sustained move above resistance with intraday volume exceeding the 20-day average of 1.83 million shares. The setup invalidates below key support at $138.28; a breach there would suggest the pattern failed and technical weakness resumes. MACD histogram at 0.2392 shows early positive divergence supporting potential upside.

Manufacturing quality remains a critical risk—May 26, 2026 disclosure revealed insulin under-delivery issues affecting specific Omnipod product lots. An active securities class action lawsuit filed for purchases between February 21, 2025 and May 26, 2026 charges Insulet executives with Securities Exchange Act violations. Goldman Sachs lowered estimates and stated it 'did not fully subscribe to the reiteration of guidance' following the device corrections. Regulatory scrutiny over manufacturing systems poses elevated ongoing risk. Negative beta of -0.42 suggests stock moves counter to broad market rallies, limiting upside participation in bullish regimes. Current volume at 1.33M versus 20-day average of 1.83M shows limited institutional accumulation supporting breakout conviction.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.